Evidence map›Paper›PMID 30303976›Full record

ArticlePloS one2018

Dynasore protects the ocular surface against damaging oxidative stress.

Andrew Webster, Shravan K Chintala, Jasmine Kim, Michelle Ngan, Tatsuo Itakura, Noorjahan Panjwani, Pablo Argüeso, Joseph T Barr, Shinwu Jeong, M Elizabeth Fini

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Andrew WebsterUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States of America.
Shravan K ChintalaUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States of America.
Jasmine KimProgram in Biological Sciences, USC Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, CA, United States of America.
Michelle NganProgram in Preventive Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States of America.
Tatsuo ItakuraUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States of America.
Noorjahan PanjwaniNew England Eye Center/Department of Ophthalmology and Department of Developmental, Molecular and Chemical Biology, Tufts University School of Medicine, Boston, MA, United States of America.
Pablo ArgüesoSchepens Eye Research Institute of Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, MA, United States of America.
Joseph T BarrThe Ohio State University College of Optometry, Columbus, OH, United States of America.
Shinwu JeongUSC Institute for Genetic Medicine and USC Roski Eye Institute/Department of Ophthalmology, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States of America.
M Elizabeth FiniUSC Institute for Genetic Medicine, Keck School of Medicine of USC, University of Southern California, Los Angeles, CA, United States of America.ORCID 0000-0001-9877-188X
University of Southern California · USMassachusetts Eye and Ear Infirmary · USThe Ohio State University · USTufts University · US

Funding

VISION RESEARCHP30EY003790 · NEI · SCHEPENS EYE RESEARCH INSTITUTE · PI Patricia Ann D'Amore · 1985 to 2026
$25.5M
Clusterin at the Ocular Surface Administrative Supplement IIR01EY026479 · NEI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI FINI, M ELIZABETH · 2016 to 2020
$2.9M
NEI NIH HHS P30 EY003790NEI NIH HHS R01 EY026479
6 · The paper itself

Abstract

Water soluble "vital" dyes are commonly used clinically to evaluate health of the ocular surface; however, staining mechanisms remain poorly understood. Recent evidence suggests that sublethal damage stimulates vital dye uptake by individual living cells. Since cell damage can also stimulate reparative plasma membrane remodeling, we hypothesized that dye uptake occurs via endocytic vesicles. In support of this idea, we show here that application of oxidative stress to relatively undifferentiated monolayer cultures of human corneal epithelial cells stimulates both dye uptake and endocytosis, and that dye uptake is blocked by co-treatment with three different endocytosis inhibitors. Stress application to stratified and differentiated corneal epithelial cell cultures, which are a better model of the ocular surface, also stimulated dye uptake; however, endocytosis was not stimulated, and two of the endocytosis inhibitors did not block dye uptake. The exception was Dynasore and its more potent analogue Dyngo-4a, both small molecules developed to target dynamin family GTPases, but also having off-target effects on the plasma membrane. Significantly, while Dynasore blocked stress-stimulated dye uptake at the ocular surface of ex vivo mouse eyes when treatment was performed at the same time as eyes were stressed, it had no effect when used after stress was applied and the ocular surface was already damaged. Thus, Dynasore could not be working by inhibiting endocytosis. Employing cytotoxicity and western blotting assays, we went on to demonstrate an alternative mechanism. We show that Dynasore is remarkably protective of cells and their surface glycocalyx, preventing damage due to stress, and thus precluding dye entry. These unexpected and novel findings provide greater insight into the mechanisms of vital dye uptake and point the direction for future study. Significantly, they also suggest that Dynasore and its analogues might be used therapeutically to protect the ocular surface and to treat ocular surface disease.

Indexed as

AnimalsCell LineDisease Models, AnimalEndocytosisEpithelial CellsEyeFluoresceinFluorescent DyesHumansHydrazonesMiceOrgan Culture TechniquesOxidative StressProtective AgentsRose BengalFluoresceinFluorescent DyesHydrazonesN'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazideProtective AgentsRose Bengal

Identifiers

PMID30303976
PMCPMC6179211
OpenAlexW2896385798

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.